Phyllis Arthur is the Executive Vice President & Head of Healthcare Policy and Programs at BIO. In this role, Phyllis is responsible for leading a robust portfolio of healthcare policy issues with member companies, including on pricing, reimbursement, access, infectious disease, national security, and capital formation. Previously, Phyllis served as the SVP for Infectious Disease and Emerging Science Policy, where she worked with member companies in vaccines, antimicrobial resistance, and biodefense on policy, legislative and regulatory issues. Phyllis joined BIO in July 2009 as the Director of Healthcare Regulatory Affairs. Prior to joining BIO, Phyllis worked in numerous marketing and sales positions for Merck & Co. in their Vaccine Division. Over her 16-year career at Merck, Ms. Arthur launched several exciting new vaccines in the United States and internationally, including the first HPV vaccine, GARDASIL. During her years in Marketing, she worked closely with clinical and academic thought leaders in infectious diseases, oncology, and public health. In addition, Phyllis also led a large vaccine sales organization of over 75 representatives and managers covering 14 states.